

June 29, 2026

To The Secretary, Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001. Scrip Code: 540975	To The Manager, Listing Department, The National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400051. Scrip Symbol: ASTERDM
---	--

Dear Sir/ Madam,

Sub: Intimation of acquisition of 3,57,143 Optionally Convertible Redeemable Preference Shares in Alfaone Medicals Private Limited, an associate company of Aster DM Healthcare Limited (“Company”)

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of the SEBI Listing Regulations, this is to inform you that the Company, today i.e., June 29, 2026, has acquired 3,57,143 Optionally Convertible Redeemable Preference Shares (OCRPS) of face value of Rs. 10/- each at price of Rs. 700/- each including security premium of Rs. 690/- each, by subscribing in rights issue of Alfaone Medicals Private Limited, an associate company of the Company.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, are given in “Annexure I”.

The above-mentioned information will also be available on the website of the Company at <https://www.asterdmhealthcare.in>.

We request you to kindly take the above information on record.

Thank you

For **Aster DM Healthcare Limited**

Hemish Purushottam

Company Secretary and Compliance Officer

M. No: A24331

Aster DM Healthcare Limited - Registered Office

No 7-1-450/20, Plot No-04, Mythri Vihar,
Sanjeev Reddy Nagar, Hyderabad, Ameerpet,
Telangana, India - 500038

Aster DM Healthcare Limited - Corporate Office

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar, Bengaluru,
Karnataka, India - 560027

Annexure I

Details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	<p>Name: Alfaone Medicals Private Limited. (“AMPL”)</p> <p>Date of incorporation: December 03, 2020</p> <p>Authorized Share Capital: Rs. 6,36,94,690/- (Rupees Six Crore Thirty-Six Lakh Ninety-Four Thousand Six Hundred and Ninety Only) comprising 24,22,369 equity shares of face value of Rs. 10/- each and 39,47,100 Optionally Convertible Redeemable Preference Shares of face value of Rs. 10/- each.</p> <p>Paid-up Share Capital: Rs. 5,75,00,410/- (Rupees Five Crore Seventy-Five Lakh Four Hundred and Ten Only) comprising 23,52,941 equity shares of face value of Rs.10/- each and 3,397,100 Optionally Convertible Redeemable Preference Shares (‘OCRPS’) of face value of Rs. 10/- each.</p> <p>Turnover:</p> <p>For the financial year ended 31 March 2026: Rs 589.55 lakhs.</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>AMPL being an associate Company, is a related party of the Company. The transaction falls within the ambit of related party transactions. The Board has approved the related party transaction.</p> <p>Apart from the aforesaid, the promoter / promoter group/ group companies do not have any interest in AMPL.</p> <p>The transaction is done at an arm’s length basis.</p>

Sr. No	Particulars	Details
3	Industry to which the entity being acquired belongs	Healthcare Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment by the Company is being made for general corporate purposes.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6	Indicative time period for completion of the acquisition;	AMPL has allotted 3,57,143 Optionally Convertible Redeemable Preference Shares of face value of Rs. 10/- each on June 29, 2026.
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
8	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 25,00,00,100/- (Rupees Twenty-Five Crore and Hundred Only). OCRPS are acquired at Rs. 700/- each (Rupees Seven Hundred Only).
9	Percentage of shareholding / control acquired and / or number of shares acquired;	3,57,143 Optionally Convertible Redeemable Preference Shares of face value of Rs.10/- each acquired at Rs. 700/- each including security premium of Rs. 690/- each. Pre-Acquisition: <u>Number and Percentage of Equity Shares:</u> 11,50,941 (48.91%) <u>Number and Percentage of OCRPS:</u> 33,97,100 (100%) Post-Acquisition: <u>Number and Percentage of Equity Shares:</u> 11,50,941 (48.91%) <u>Number and Percentage of OCRPS:</u> 37,54,243 (100%)

10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	AMPL has been incorporated on December 03, 2020, in Bengaluru, Karnataka, India, <i>inter alia</i> , to carry on the business of trading drugs and pharmaceuticals. Turnover: FY2025-26: Rs. 589.55 lakhs FY2024-25: Rs. 616.32 lakhs FY2023-24: Rs. 621.79 lakhs
----	---	--

===